Last reviewed · How we verify
Long-term course of antiandrogen drugs
Long-term course of antiandrogen drugs is a Antiandrogen Small molecule drug developed by The First Affiliated Hospital with Nanjing Medical University. It is currently in Phase 3 development for Prostate cancer (hormone-sensitive), Androgen-dependent conditions requiring long-term hormonal suppression. Also known as: Rezvilutamide.
Antiandrogen drugs block the effects of androgens (male hormones) by inhibiting androgen receptor signaling.
Antiandrogen drugs block the effects of androgens (male hormones) by inhibiting androgen receptor signaling. Used for Prostate cancer (hormone-sensitive), Androgen-dependent conditions requiring long-term hormonal suppression.
At a glance
| Generic name | Long-term course of antiandrogen drugs |
|---|---|
| Also known as | Rezvilutamide |
| Sponsor | The First Affiliated Hospital with Nanjing Medical University |
| Drug class | Antiandrogen |
| Target | Androgen receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Antiandrogens work by competitively binding to androgen receptors or inhibiting androgen synthesis, thereby reducing the biological activity of testosterone and other androgens. This mechanism is used to suppress androgen-dependent cell growth and proliferation. Long-term courses are typically employed in hormone-sensitive conditions where sustained androgen suppression is therapeutically beneficial.
Approved indications
- Prostate cancer (hormone-sensitive)
- Androgen-dependent conditions requiring long-term hormonal suppression
Common side effects
- Hot flashes
- Erectile dysfunction
- Gynecomastia
- Fatigue
- Decreased libido
Key clinical trials
- Comparing a 6-month vs Long-term Course of Rezvilutamide With ADT Plus Chemotherapy in mHSPC (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Long-term course of antiandrogen drugs CI brief — competitive landscape report
- Long-term course of antiandrogen drugs updates RSS · CI watch RSS
- The First Affiliated Hospital with Nanjing Medical University portfolio CI
Frequently asked questions about Long-term course of antiandrogen drugs
What is Long-term course of antiandrogen drugs?
How does Long-term course of antiandrogen drugs work?
What is Long-term course of antiandrogen drugs used for?
Who makes Long-term course of antiandrogen drugs?
Is Long-term course of antiandrogen drugs also known as anything else?
What drug class is Long-term course of antiandrogen drugs in?
What development phase is Long-term course of antiandrogen drugs in?
What are the side effects of Long-term course of antiandrogen drugs?
What does Long-term course of antiandrogen drugs target?
Related
- Drug class: All Antiandrogen drugs
- Target: All drugs targeting Androgen receptor
- Manufacturer: The First Affiliated Hospital with Nanjing Medical University — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Prostate cancer (hormone-sensitive)
- Indication: Drugs for Androgen-dependent conditions requiring long-term hormonal suppression
- Also known as: Rezvilutamide
- Compare: Long-term course of antiandrogen drugs vs similar drugs
- Pricing: Long-term course of antiandrogen drugs cost, discount & access